Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-12-15 00:00:00 ET · period of report 2023-12-13 · accession 0000875320-23-000060 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-12-15 | 2023-12-13 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $399.42 | -13.4K | 9,171 | -59% | -$5.33M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-13 | S | D | 100 | $400.19 | 9,071 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-13 | S | D | 13,254 | $399.41 | 9,171 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $399.41 (range $399.00 to $399.97). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |